IL2 and ovarian cancer: Wang et al. designed anti-uPAR CAR (ATF-CAR) T-cells constructed by combining an antigen recognition domain with ATF to transduce T-cells, and this treatment exhibited strong cytotoxicity toward uPAR-expressing ovarian cancer cells and released higher levels of Th1 cytokines [interferon-γ (IFN-γ), tumour necrosis factor (TNF) and interleukin-2 (IL-2)] and granzyme B than control T-cells [218].